DE59907958D1 - USE OF TUMOR CELLS TIME-RELATED IN COMBINATION WITH INTAKE ANTIBODIES FOR IMMUNIZATION - Google Patents

USE OF TUMOR CELLS TIME-RELATED IN COMBINATION WITH INTAKE ANTIBODIES FOR IMMUNIZATION

Info

Publication number
DE59907958D1
DE59907958D1 DE59907958T DE59907958T DE59907958D1 DE 59907958 D1 DE59907958 D1 DE 59907958D1 DE 59907958 T DE59907958 T DE 59907958T DE 59907958 T DE59907958 T DE 59907958T DE 59907958 D1 DE59907958 D1 DE 59907958D1
Authority
DE
Germany
Prior art keywords
immunization
antibodies
intake
combination
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59907958T
Other languages
German (de)
Inventor
Horst Lindhofer
Peter Ruf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trion Pharma GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/EP1999/007094 external-priority patent/WO2000018435A1/en
Application granted granted Critical
Publication of DE59907958D1 publication Critical patent/DE59907958D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE59907958T 1998-09-25 1999-09-22 USE OF TUMOR CELLS TIME-RELATED IN COMBINATION WITH INTAKE ANTIBODIES FOR IMMUNIZATION Expired - Lifetime DE59907958D1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19844157 1998-09-25
DE19859115A DE19859115A1 (en) 1998-09-25 1998-12-21 Use of delayed tumor cells in combination with intact antibodies for immunization
PCT/EP1999/007094 WO2000018435A1 (en) 1998-09-25 1999-09-22 Time-staggered utilization of tumor cells in combination with intact antibodies for immunization

Publications (1)

Publication Number Publication Date
DE59907958D1 true DE59907958D1 (en) 2004-01-15

Family

ID=7882314

Family Applications (3)

Application Number Title Priority Date Filing Date
DE19859115A Ceased DE19859115A1 (en) 1998-09-25 1998-12-21 Use of delayed tumor cells in combination with intact antibodies for immunization
DE19859110A Withdrawn DE19859110A1 (en) 1998-09-25 1998-12-21 Bispecific and trispecific antibodies that react specifically with inducible surface antigens as operational targets
DE59907958T Expired - Lifetime DE59907958D1 (en) 1998-09-25 1999-09-22 USE OF TUMOR CELLS TIME-RELATED IN COMBINATION WITH INTAKE ANTIBODIES FOR IMMUNIZATION

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE19859115A Ceased DE19859115A1 (en) 1998-09-25 1998-12-21 Use of delayed tumor cells in combination with intact antibodies for immunization
DE19859110A Withdrawn DE19859110A1 (en) 1998-09-25 1998-12-21 Bispecific and trispecific antibodies that react specifically with inducible surface antigens as operational targets

Country Status (1)

Country Link
DE (3) DE19859115A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10043437A1 (en) * 2000-09-04 2002-03-28 Horst Lindhofer Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
DE10261223A1 (en) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Increasing the immune response through substances that influence the function of natural killer cells
EP1820513A1 (en) * 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
CN101802015B (en) * 2007-03-29 2015-05-06 根马布股份公司 Bispecific antibodies and methods for production thereof
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
DK3233907T3 (en) 2014-12-19 2021-06-07 Genmab As Bispecific heterodimeric proteins in rodents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19710449A1 (en) * 1997-03-13 1998-09-17 Basf Ag Process for the purification of sodium hydroxide solution

Also Published As

Publication number Publication date
DE19859110A1 (en) 2000-04-13
DE19859115A1 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
DE69502510T2 (en) BORDER LAYER FOR USE IN REFRIGERATOR
ATE255420T1 (en) USE OF TUMOR CELLS IN COMBINATION WITH INTACT ANTIBODIES FOR IMMUNIZATION
DE69736197D1 (en) Anti-coagulating humanized antibodies to factor IX, for use in the treatment of thrombosis
ATE280181T1 (en) ARTIFICIAL PEPTIDES WITH SURFACE ACTIVITY AND THEIR USE FOR PRODUCING ARTIFICIAL SURFACTANTS
DE69920897D1 (en) MONOCLONAL ANTIBODIES WITH REDUCED IMMUNIZABILITY
DE69810957D1 (en) HIGHLY EFFICIENT ABSORBENT ARTICLE FOR USE WITH MONTHSHOSE
DE69836272D1 (en) EXPERIMENTAL ASSEMBLY FOR THE DETERMINATION OF ANALYTES IN BODY FLUIDS
ATE213271T1 (en) METHOD FOR PRODUCING RECOMBINANT PROTEINS IN E. COLI USING HIGH CELL DENSITY FERMENTATION
NO20001242D0 (en) April - a new protein with growth effects
DE60032226D1 (en) METHOD FOR THE INDUCTION OF CANCER CELL AND TUMOR REGRESSION
DE69909716D1 (en) Formant speech synthesizer using concatenation of half-syllables with independent cross-fading in the filter coefficient and source range
ID24474A (en) PYROLSIS CORRUPTION SEA WITH RADIANT COIL IN THE FORM OF INTERNAL FLASHING
DE69819332D1 (en) IMPROVED ANTIBODIES AGAINST IgE AND METHOD FOR IMPROVING ANTIBODIES
ATE217012T1 (en) IMPROVED METHOD FOR OBTAINING INSULIN PRECURSORS WITH CORRECTLY LINKED CYSTINE BRIDGES
DE59813187D1 (en) PROCESS FOR THE PREPARATION OF POLYPEPTIDES WITH APPROPRIATE GLYCOSILATION
DE69725329D1 (en) DIRECTIVE MARKING WITH OUTSTANDING ELEVATIONS AND METHOD FOR THE PRODUCTION
ATE372382T1 (en) A FACTOR VIII POLYPEPTIDE WITH FACTOR VIII:C ACTIVITY
DE59911879D1 (en) USE OF BIOGENIC ESTROGEN SULFAMATE FOR HORMONE SUBSTITUTION THERAPY
DE59706572D1 (en) USE OF CARBOXYAMIDE POLYSILOXANES FOR LEATHER HYDROPHOBICATION
DE69800720T2 (en) Blood cell staining reagent
DE59907958D1 (en) USE OF TUMOR CELLS TIME-RELATED IN COMBINATION WITH INTAKE ANTIBODIES FOR IMMUNIZATION
DE69712578T2 (en) Use of at least one pyrimidine-3-oxide substituted in the 6-position for stimulating tyrosinase
DE3684578D1 (en) MONOCLONAL ANTIBODIES WITH BINDING SPECIFICITY FOR HUMAN PROSTATATUM ORIGINAL AND METHODS FOR THEIR USE.
DE69939111D1 (en) Use of hapten-treated tumor cells and extracts
WO2000032635A3 (en) Tumor specific human monoclonal antibodies and methods of use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TRION PHARMA GMBH, 80807 MUENCHEN, DE